Viewing Study NCT06058793


Ignite Creation Date: 2025-12-25 @ 1:22 AM
Ignite Modification Date: 2026-01-06 @ 8:13 AM
Study NCT ID: NCT06058793
Status: COMPLETED
Last Update Posted: 2025-12-19
First Post: 2023-09-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Sponsor: Boehringer Ingelheim
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module